GlassScriptPhysician profile
Rahul Guha
NPI 1457779506
$57,348.32
in general payments reported to CMS, 2019-2025
34 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $161 · 2021: $835 · 2022: $22K · 2023: $32K · 2024: $1,133 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,945 · Travel and Lodging: $1,546 · Education: $12.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $17,325.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,766.00 |
| Food and Beverage | $3,944.97 |
| Travel and Lodging | $1,546.47 |
| Education | $12.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $35,613.14 | 2020-2024 | Xcopri |
| Neurelis, INC. | $16,444.22 | 2021-2025 | Valtoco |
| Livanova USA, INC. | $1,146.00 | 2020-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,115.40 | 2021-2025 | |
| Ucb, INC. | $792.32 | 2020-2025 | Briviact, Fintepla, Nayzilam |
| Pfizer INC. | $378.67 | 2021-2025 | |
| Lundbeck LLC | $351.97 | 2022-2024 | Vyepti |
| Upsher-Smith Laboratories LLC | $150.25 | 2021-2023 | |
| Lilly USA, LLC | $148.86 | 2020-2024 | Emgality, Reyvow |
| Supernus Pharmaceuticals, INC. | $147.70 | 2021-2022 | |
| Amgen INC. | $117.19 | 2021-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $103.08 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Aucta Pharmaceuticals, INC. | $93.87 | 2024-2025 | Motpoly Xr |
| Jazz Pharmaceuticals INC. | $73.39 | 2022-2024 | |
| Eisai INC. | $65.77 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $64.48 | 2023-2024 | Aptiom |
| Biohaven Pharmaceuticals, INC. | $56.88 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.70 | 2022 | |
| Merz Pharmaceuticals, LLC | $50.32 | 2021-2025 | Xeomin |
| Tanabe Pharma America, INC. | $48.76 | 2024-2025 | Radicava |
| Tonix Medicines, INC. | $44.41 | 2024-2025 | Zembrace Symtouch |
| Servier Pharmaceuticals LLC | $37.55 | 2024-2025 | |
| Kyowa Kirin, INC. | $36.48 | 2021-2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $35.17 | 2024-2025 | Crexont, Rytary |
| Zogenix INC. | $24.14 | 2021 | |
| Sunovion Pharmaceuticals INC. | $23.60 | 2021 | |
| Banner Life Sciences, LLC | $22.36 | 2022 | |
| Ceribell, INC. | $18.58 | 2025 | Pocket Eeg Device |
| Electromed, INC. | $18.22 | 2024 | Smartvest |
| Argenx US, INC. | $16.38 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $15.95 | 2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $14.99 | 2024 | Nuedexta |
| Neurocrine Biosciences, INC. | $14.96 | 2024 | Ingrezza |
| Greenwich Biosciences, INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Guha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.